Literature DB >> 6610555

The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects.

M Frisk-Holmberg, Y Bergqvist, E Termond, B Domeij-Nyberg.   

Abstract

The kinetics and disposition of chloroquine (CQ) and its metabolite monodesethylchloroquine (CQM) were investigated in 5 healthy volunteers after incremental (150-300-600mg CQ base) single oral doses of CQ. The analytical method used (HPLC and fluorescence detection) is the most sensitive known method for CQ and CQM. Plasma and whole blood concentrations of CQ, CQM and a third metabolite, bidesethylchloroquine (CQMM), were determined. The kinetics of CQ was found to be unique. The best fit was obtained by a multicompartmental model. The biological half-life appeared to be between 30-60 days; the volume of distribution (Vd) was approximately 8001/kg, and the clearance approximately 11/h/kg when calculated from plasma data. The whole blood concentrations were approximately 8-10 times higher than in plasma, and consequently the Vd and whole blood clearance were approximately 10 times lower. The kinetics changed as the dose was increased. An indication of capacity-limited steps in CQ disposition was found, as the rate constants decreased even though the clearance remained the same. The intrinsic half-life of CQM was 1/4 of that of CQ, but was prolonged after the highest dose of CQ. The present knowledge of CQ kinetics could provide a basis for revision of current dosage regimens in malaria suppression and rheumatoid disease to ensure efficacious and safe therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6610555     DOI: 10.1007/BF00542151

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  STUDIES ON THE CHEMOTHERAPY OF THE HUMAN MALARIAS. VI. THE PHYSIOLOGICAL DISPOSITION, ANTIMALARIAL ACTIVITY, AND TOXICITY OF SEVERAL DERIVATIVES OF 4-AMINOQUINOLINE.

Authors:  R W Berliner; D P Earle; J V Taggart; C G Zubrod; W J Welch; N J Conan; E Bauman; S T Scudder; J A Shannon
Journal:  J Clin Invest       Date:  1948-05       Impact factor: 14.808

2.  Detection and distribution of chloroquine metabolites in human tissues.

Authors:  K KURODA
Journal:  J Pharmacol Exp Ther       Date:  1962-08       Impact factor: 4.030

3.  Pharmacokinetics of antimalarials and proposals for dosage regimens.

Authors:  W A Ritschel; G V Hammer; G A Thompson
Journal:  Int J Clin Pharmacol Biopharm       Date:  1978-09

4.  Kinetics of a new antimalarial, mefloquine.

Authors:  R E Desjardins; C L Pamplin; J von Bredow; K G Barry; C J Canfield
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

5.  Steady state disposition of chloroquine in patients with rheumatoid disease.

Authors:  M Frisk-Holmberg; Y Bergqvist; B Domeij-Nyberg
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  The urinary excretion of chloroquine in different ethnic groups.

Authors:  D A Evans; K A Fletcher; J D Baty
Journal:  Ann Trop Med Parasitol       Date:  1979-02

7.  Determination of chloroquine and its desethyl metabolite in plasma, red blood cells and urine by liquid chromatography.

Authors:  G Alván; L Ekman; B Lindström
Journal:  J Chromatogr       Date:  1982-04-16

8.  Determination of chloroquine and its de-ethylated metabolites in human plasma by ion-pair high-performance liquid chromatography.

Authors:  N D Brown; B T Poon; J D Chulay
Journal:  J Chromatogr       Date:  1982-04-16

9.  The metabolism of chloroquine in man during and after repeated oral dosage.

Authors:  E W McChesney; M J Fasco; W F Banks
Journal:  J Pharmacol Exp Ther       Date:  1967-11       Impact factor: 4.030

10.  Distribution of chloroquine and its metabolite desethyl-chloroquine in human blood cells and its implication for the quantitative determination of these compounds in serum and plasma.

Authors:  Y Bergqvist; B Domeij-Nyberg
Journal:  J Chromatogr       Date:  1983-01-14
View more
  58 in total

1.  Efficacy of a loading dose of oral chloroquine in a 36-hour treatment schedule for uncomplicated plasmodium falciparum malaria.

Authors:  E Pussard; J P Lepers; F Clavier; L Raharimalala; J Le Bras; M Frisk-Holmberg; Y Bergqvist; F Verdier
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Pharmacokinetics of intramuscular amopyroquin in healthy subjects and determination of a therapeutic regimen for Plasmodium falciparum malaria.

Authors:  F Verdier; E Pussard; F Clavier; J Le Bras; C Gaudebout
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

3.  Characterization of the Preclinical Pharmacology of the New 2-Aminomethylphenol, JPC-3210, for Malaria Treatment and Prevention.

Authors:  Geoffrey W Birrell; Gavin D Heffernan; Guy A Schiehser; John Anderson; Arba L Ager; Pablo Morales; Donna MacKenzie; Karin van Breda; Marina Chavchich; Laura R Jacobus; G Dennis Shanks; David P Jacobus; Michael D Edstein
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

4.  Pitfalls in estimating piperaquine elimination.

Authors:  Joel Tarning; Niklas Lindegårdh; Anna Annerberg; Thida Singtoroj; Nicholas P J Day; Michael Ashton; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 5.  Chloroquine resistance in Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of antimalarial drugs.

Authors:  N J White
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

7.  Chloroquine is grossly overdosed and overused but well tolerated in Guinea-bissau.

Authors:  Johan Ursing; Poul-Erik Kofoed; Amabelia Rodrigues; Yngve Bergqvist; Lars Rombo
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

8.  Chloroquine in malaria. Isn't it time for revision of prophylaxis schedules?

Authors:  M Frisk; G Gunnert
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  High absolute bioavailability of methylene blue given as an aqueous oral formulation.

Authors:  Ingeborg Walter-Sack; Jens Rengelshausen; Heike Oberwittler; Juergen Burhenne; Olaf Mueller; Peter Meissner; Gerd Mikus
Journal:  Eur J Clin Pharmacol       Date:  2008-09-23       Impact factor: 2.953

10.  Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy.

Authors:  Harin A Karunajeewa; Sam Salman; Ivo Mueller; Francisca Baiwog; Servina Gomorrai; Irwin Law; Madhu Page-Sharp; Stephen Rogerson; Peter Siba; Kenneth F Ilett; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.